MSN Labs enters into licensing agreement with Lilly

The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19

Hyderabad: Hyderabad-based MSN Labs (MSN) entered into a royalty-free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for Covid-19 in India.

The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

---

Dr MSN Reddy, CMD, MSN Group, commented “This collaboration with Eli Lilly and Company is a landmark milestone in India’s fight against Covid-19 and will thus help in increasing the availability and affordability of baricitinib”.

MSN will be launching the product under the brand name Baridoz in two strengths 2 mg and 4mg. The company has developed the active pharmaceutical ingredient and the formulation of baricitinib in its in-house R&D and manufacturing units.

As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg and Oselow (Oseltamivir) as 75 mg capsules.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .